Baldwin Wealth Partners LLC MA Raises Position in Beyond Air, Inc. (NASDAQ:XAIR)

Baldwin Wealth Partners LLC MA raised its position in Beyond Air, Inc. (NASDAQ:XAIR) by 721.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 308,000 shares of the company’s stock after buying an additional 270,500 shares during the period. Baldwin Wealth Partners LLC MA’s holdings in Beyond Air were worth $110,000 at the end of the most recent reporting period.

Separately, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Beyond Air in the second quarter worth approximately $47,000. Institutional investors own 31.50% of the company’s stock.

Beyond Air Trading Down 7.8 %

Shares of XAIR stock opened at $0.40 on Tuesday. Beyond Air, Inc. has a fifty-two week low of $0.30 and a fifty-two week high of $2.17. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.38 and a current ratio of 5.76. The stock’s fifty day moving average is $0.45 and its two-hundred day moving average is $0.45. The firm has a market capitalization of $28.88 million, a P/E ratio of -0.28 and a beta of -0.17.

Beyond Air (NASDAQ:XAIR) last posted its quarterly earnings results on Monday, November 11th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02. The business had revenue of $0.80 million during the quarter, compared to analyst estimates of $1.19 million. Beyond Air had a negative return on equity of 227.29% and a negative net margin of 2,369.17%. During the same period in the prior year, the business earned ($0.51) earnings per share. Research analysts expect that Beyond Air, Inc. will post -0.78 earnings per share for the current fiscal year.

Beyond Air Profile

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.